尤瑞克林联合巴曲酶治疗急性脑梗死的临床研究

目的 观察尤瑞克林联合巴曲酶治疗急性脑梗死的疗效及安全性。方法 采用随机分组1∶1对照研究方法，共入选74例患者，试验组(n=37)为尤瑞克林与巴曲酶联合治疗，对照组(n=37)为巴曲酶单独治疗，于治疗前、治疗后第21、90天分别采用美国国立卫生院神经功能缺损评分(Nati0nal Institutes of Heal...

Clinical Trial of Urinary Kallikrein Combined with Batroxobin Therapy in Acute Ischemic Stroke

Objective To observe the effect and safety of urinary kallikrein combined with batroxobin in acute ischemic stroke patients. Methods A randomized 1：1 control clinical study was performed in 74 patients. The study group （n=37） was administrated kallikrein combined with batroxobin and the placebo group was administrated batroxobin. National Institutes of Health Stroke Scale （NIHSS） and Barthel Index （BI）, which were used to evaluate defect of neurological function and daily living activity, were compared between study group and placebo group before treatment, and after treatment on 21th day and 90th day, in addition curative effect and adverse reaction were evaluated. Results NIHSS on the 21th day of study group and placebo group was 2.54±2.48 and 4.17±4.21 （P=0.038） respectively. NIHSS on the 90th day of study group and placebo group was 1.40±1.54 and 2.65±3.96 （P=-0.013） respectively. NIHSS of study group was significant lower than placebo group. BI on 21th day of study group and placebo group was 86.49±12.74 and 78.37±19.35 （P=0.027） respectively. BI on 90th day of study group and placebo group was 94.73±7.06 and 87.02±17.38 （P=0.002）. BI of study group was significant higher than placebo group. Clinical effective rate （almost recovery and significant improvement） of study group （89.2%） was significant higher than placebo group （62.1%） （P=0.011）. One patient in study group had symptoms of flushed face, nausea and vomiting, but got improvement after symptomatic treatment. Conclusion Urinary kallikrein combined with batroxobin was more effective than batroxobin alone in acute ischemic stroke and had no obvious side effect.